Shares of Achaogen Inc (NASDAQ:AKAO) reached a new 52-week low on Wednesday . The stock traded as low as $1.70 and last traded at $1.87, with a volume of 878217 shares changing hands. The stock had previously closed at $1.93.
AKAO has been the topic of several recent research reports. Mizuho restated a “neutral” rating and set a $8.00 price target on shares of Achaogen in a report on Tuesday, November 6th. Stifel Nicolaus increased their price target on Achaogen from $14.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, August 7th. Zacks Investment Research upgraded Achaogen from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a report on Wednesday, October 10th. Wedbush lowered Achaogen from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $17.00 to $3.00 in a report on Monday. Finally, Cowen lowered Achaogen from an “outperform” rating to a “market perform” rating in a report on Friday, November 9th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $9.25.
The stock has a market cap of $89.01 million, a P/E ratio of -0.50 and a beta of 0.67. The company has a quick ratio of 2.52, a current ratio of 2.54 and a debt-to-equity ratio of 1.00.
Achaogen Company Profile (NASDAQ:AKAO)
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.